Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Teclistamab

Catalog #:   DHF92402 Specific References (55) DATASHEET
Host species: Chimeric
Isotype: IgG4-lambda
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHF92402

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG4-lambda

Clonality

Monoclonal

Target

Tumor necrosis factor receptor superfamily member 17, TNFRSF17, CD269, B-cell maturation protein, BCMA, BCM, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q02223 & P07766

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Bispecific, BCMA, JNJ-64007957, JNJ-7957, Ab-957, CAS: 2119595-80-9

Clone ID

Teclistamab

Data Image
  • SDS-PAGE
    SDS PAGE for Teclistamab
  • Bioactivity
    Detects TNFRSF17 in indirect ELISAs.
References

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma, PMID: 32956453

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma, PMID: 33227097

MajesTEC results with teclistamab in RRMM, PMID: 34453130

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study, PMID: 34388396

A BCMA-Targeted Bispecific Antibody Is Active in Multiple Myeloma, PMID: 34417227

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies., PMID:40508128

Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States., PMID:40495704

One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn's-like inflammatory bowel disease., PMID:40450406

Sequential Myelomatous Pleural and Pericardial Effusions in Multiple Myeloma: A Case Report Demonstrating Extended Survival with Teclistamab., PMID:40421459

Teclistamab-Induced Remission of Chronic Immune Thrombocytopenia in a Patient With Multiple Myeloma., PMID:40421450

Matching-Adjusted Indirect Comparison of Elranatamab versus Teclistamab in Patients with Triple-Class Exposed/Refractory Multiple Myeloma: Updated Results., PMID:40384938

Using bispecific antibodies in a patient with peritoneal dialysis for relapsed multiple myeloma., PMID:40356496

Effectiveness and safety of teclistamab for relapsed or refractory multiple myeloma: a systematic review and meta-analysis., PMID:40352937

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium., PMID:40346049

Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract., PMID:40345961

Teclistamab Dosing in Responders: Modeling and Simulation Results from the MajesTEC-1 Study in Relapsed/Refractory Multiple Myeloma., PMID:40332715

[Immunosubstitution of patients with refractory multiple myeloma treated with teclistamab, a bispecific antibody]., PMID:40318828

Pulmonary adverse events associated with monoclonal antibodies approved for multiple myeloma: a pharmacovigilance study based on the FDA adverse event reporting system., PMID:40302414

Prolonged COVID-19 Pneumonia in Patients with Hematologic Malignancies: Clinical Significance and Serial CT Findings., PMID:40283531

Emicizumab and Acquired Hemophilia A Secondary to Multiple Myeloma., PMID:40273904

Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma., PMID:40268898

The first case of Teclistamab interference with serum electrophoresis and immunofixation., PMID:40241333

Outpatient Management of Bispecific Related Toxicities: An Observational Study of Safety Outcomes and Resource Utilization., PMID:40233295

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review., PMID:40227780

Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma., PMID:40225701

Teclistamab versus B-cell maturation antigen-targeting chimeric antigen receptor T-cell therapy in multiple myeloma: a comparative effectiveness analysis., PMID:40207713

Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients., PMID:40199861

Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment., PMID:40198766

Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician's Choice of Treatment in Spain., PMID:40193043

Characteristics of second primary malignancies following bispecific antibodies therapy., PMID:40187754

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study., PMID:40175336

Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis., PMID:40113913

Teclistamab therapy for refractory type 1 cryoglobulinemia., PMID:40109179

Unveiling cardiovascular and respiratory toxicities with monoclonal antibodies in multiple myeloma: disproportionality analysis from the FDA Adverse Event Reporting System., PMID:40095047

Treatment of Multiple Myeloma in Patients Refractory to Daratumumab/Anti-CD38 Monoclonal Antibodies: A Systematic Review., PMID:40052837

Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing., PMID:40048741

Teclistamab for relapsed or refractory multiple myeloma., PMID:40040734

Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma., PMID:40038247

Teclistamab in relapsed systemic sclerosis after autologous haematopoietic stem cell transplantation., PMID:40000264

Synergistic effect of teclistamab with PD-1 inhibition: a case of acute interstitial nephritis with dual immunotherapy., PMID:39974847

Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma., PMID:39911104

Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead., PMID:39880754

Monitoring M-Protein, Therapeutic Antibodies, and Polyclonal Antibodies in a Multiparametric Mass Spectrometry Assay Provides Insight into Therapy Response Kinetics in Patients with Multiple Myeloma., PMID:39861781

Injection site reaction to teclistamab in a patient with multiple myeloma., PMID:39845465

Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era., PMID:39809660

Incidence of Acute Kidney Injury in Relapsed and Refractory Multiple Myeloma treated with Teclistamab versus CAR T-cells., PMID:39805729

Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma., PMID:39778168

Teclistamab as Successful Treatment of Relapsed TEMPI Syndrome., PMID:39774321

Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis., PMID:39756041

Update on B-cell maturation antigen-directed therapies in AL amyloidosis., PMID:39748220

Practical insights into bispecific antibody therapy in multiple myeloma., PMID:39729045

Real-World Safety and Health Care Resource Utilization of Teclistamab Under an Outpatient Model for Step-Up Dosing Administration., PMID:39705632

Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab., PMID:39691339

Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives., PMID:39676006

Datasheet

Document Download

Research Grade Teclistamab.pdf

 

$ 484
Product specifications
100 μg 484 1 mg 1932

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Teclistamab [DHF92402]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only